Publications by authors named "Christopher C Subject"

Background: The effectiveness and safety of mineralocorticoid receptor antagonists (MRA) in acute heart failure (HF) is uncertain. We sought to describe the prescription of spironolactone during acute HF and whether early treatment is effective and safe in a real-world setting.

Methods: We performed a retrospective cohort study of adult (≥18 years) nonpregnant patients hospitalized with new-onset HF with reduced ejection fraction (HFrEF, defined by ejection fraction ≤40%) within 15 Kaiser Permanente Southern California medical centers between 2016 and 2021.

View Article and Find Full Text PDF
Article Synopsis
  • In a study examining newly diagnosed heart failure patients, researchers found that coronary artery disease (CAD) testing is not commonly used, despite its potential benefits.
  • The study analyzed data from 2729 hospitalized patients with HFrEF and found that those who underwent CAD testing had a significantly lower risk of hospital readmission or death over a follow-up period.
  • However, the timing of the testing (early vs. late) did not influence the outcomes, suggesting that testing within 90 days of hospitalization is valuable regardless of when it occurs.
View Article and Find Full Text PDF

Background: Understanding the implications of disease-specific factors beyond baseline patient characteristics for coronavirus disease 2019 (COVID-19) may allow for identification of indicators for safe hospital discharge.

Objective: Assess whether disease-specific factors are associated with adverse events post-discharge using a data-driven approach.

Design: Retrospective cohort study.

View Article and Find Full Text PDF

Importance: Current guidelines recommend use of dexamethasone, 6 mg/d, up to 10 days or until discharge for patients hospitalized with COVID-19. Whether patients who received less than 10 days of corticosteroids during hospitalization for COVID-19 benefit from continuing treatment at discharge has not been determined.

Objective: To assess whether continuing dexamethasone treatment at discharge is associated with reduced all-cause readmissions or mortality postdischarge.

View Article and Find Full Text PDF